These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27248906)

  • 1. Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome.
    Albitar F; Ma W; Diep K; De Dios I; Agersborg S; Thangavelu M; Brodie S; Albitar M
    Genet Test Mol Biomarkers; 2016 Jul; 20(7):341-5. PubMed ID: 27248906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome.
    Iriyama C; Tomita A; Hoshino H; Adachi-Shirahata M; Furukawa-Hibi Y; Yamada K; Kiyoi H; Naoe T
    Biochem Biophys Res Commun; 2012 Mar; 419(4):662-9. PubMed ID: 22382018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational profiling in patients with MDS: ready for every-day use in the clinic?
    Bacher U; Kohlmann A; Haferlach T
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):32-42. PubMed ID: 25659728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS).
    Mohamedali AM; Gäken J; Ahmed M; Malik F; Smith AE; Best S; Mian S; Gaymes T; Ireland R; Kulasekararaj AG; Mufti GJ
    Leukemia; 2015 Sep; 29(9):1928-38. PubMed ID: 25943179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome.
    Kawata E; Lazo-Langner A; Xenocostas A; Hsia CC; Howson-Jan K; Deotare U; Saini L; Yang P; Broadbent R; Levy M; Howlett C; Stuart A; Kerkhof J; Santos S; Lin H; Sadikovic B; Chin-Yee I
    Br J Haematol; 2021 Feb; 192(4):729-736. PubMed ID: 32588428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes.
    Guo Y; Bosompem A; Mohan S; Erdogan B; Ye F; Vickers KC; Sheng Q; Zhao S; Li CI; Su PF; Jagasia M; Strickland SA; Griffiths EA; Kim AS
    BMC Genomics; 2015 Sep; 16():727. PubMed ID: 26400237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving role of next generation sequencing in myelodysplastic syndromes.
    Spaulding TP; Stockton SS; Savona MR
    Br J Haematol; 2020 Jan; 188(2):224-239. PubMed ID: 31571207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Detection of Myelodysplastic Syndrome/Leukemia-associated Mutations Using NGS Is Critical in Treating Aplastic Anemia.
    Li X; Wu YH; Cai SS; Li WM; You Y; Zhang M
    Curr Med Sci; 2019 Apr; 39(2):217-221. PubMed ID: 31016513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes.
    Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A
    Cytometry B Clin Cytom; 2005 Mar; 64(1):9-17. PubMed ID: 15668954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Getting personal with myelodysplastic syndromes: is now the right time?
    Chokr N; Pine AB; Bewersdorf JP; Shallis RM; Stahl M; Zeidan AM
    Expert Rev Hematol; 2019 Apr; 12(4):215-224. PubMed ID: 30977414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A novel prognostic model incorporating genetic profiling for myelodysplastic syndromes].
    Nagata Y; Ogawa S
    Rinsho Ketsueki; 2017; 58(7):776-786. PubMed ID: 28781274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of myelodysplastic syndrome in the era of next-generation sequencing.
    Tobiasson M; Kittang AO
    J Intern Med; 2019 Jul; 286(1):41-62. PubMed ID: 30869816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes.
    Suzuki Y; Tomita A; Nakamura F; Iriyama C; Shirahata-Adachi M; Shimada K; Akashi A; Ishikawa Y; Kaneda N; Kiyoi H
    Cancer Sci; 2016 Sep; 107(9):1329-37. PubMed ID: 27323954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Next-Generation Sequencing Is a Sensitive Tool for Differential Diagnosis of Myelodysplastic Syndromes in Bone Marrow Trephines.
    Bräuninger A; Blau W; Kunze K; Desch AK; Brobeil A; Tur MK; Etschmann B; Günther U; Körholz D; Schliesser G; Käbisch A; Kiehl M; Rummel M; Gattenlöhner S
    J Mol Diagn; 2018 May; 20(3):344-354. PubMed ID: 29471115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].
    Lu D; Qin YZ; Li LD; Shi HX; Lai YY; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):370-6. PubMed ID: 24763007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
    Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
    BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inspecting Targeted Deep Sequencing of Whole Genome Amplified DNA Versus Fresh DNA for Somatic Mutation Detection: A Genetic Study in Myelodysplastic Syndrome Patients.
    Palomo L; Fuster-Tormo F; Alvira D; Ademà V; Armengol MP; Gómez-Marzo P; de Haro N; Mallo M; Xicoy B; Zamora L; Solé F
    Biopreserv Biobank; 2017 Aug; 15(4):360-365. PubMed ID: 28586236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the mutational profile of lower-risk myelodysplastic neoplasm patients with respect to disease progression using next-generation sequencing and pyrosequencing.
    Adamska M; Kowal-Wiśniewska E; Czerwińska-Rybak J; Kiwerska K; Barańska M; Gronowska W; Loba J; Brzeźniakiewicz-Janus K; Wasilewska E; Łanocha A; Jarmuż-Szymczak M; Gil L
    Contemp Oncol (Pozn); 2023; 27(4):269-279. PubMed ID: 38405213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.